Login to Your Account

Cubist Meeting With FDA After Cidecin Fails To Meet Endpoint

By Karen Young

Friday, January 18, 2002
Cubist Pharmaceuticals Inc. said its investigational antibiotic, Cidecin, failed to meet its primary endpoint in the first of two pivotal Phase III trials for community-acquired pneumonia.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription